If You Invested in Syros Pharmaceut (SYRS)

Syros Pharmaceuticals, Inc. (SYRS) is a biopharmaceutical company that has focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. According to the company’s public statements, Syros concentrated its efforts on blood cancers that have been difficult to treat with other targeted approaches, with a particular emphasis on higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML) in patients whose disease is characterized by RARA gene overexpression.

Syros has described its mission as being driven by the goal of helping patients with blood disorders that have largely eluded other targeted therapies. The company’s primary therapeutic candidate has been tamibarotene, an oral, selective retinoic acid receptor alpha (RARα) agonist. Syros has evaluated tamibarotene in multiple clinical settings, including frontline HR-MDS and AML, generally in combination with established agents such as azacitidine, and in some studies with venetoclax and azacitidine.

Core therapeutic focus

Across its public updates, Syros has consistently highlighted its focus on:

• Higher-risk myelodysplastic syndrome (HR-MDS) with RARA gene overexpression, where tamibarotene has been studied in combination with azacitidine in the pivotal Phase 3 SELECT-MDS-1 trial.
• Acute myeloid leukemia (AML) with RARA gene overexpression, where tamibarotene has been evaluated in clinical trials such as SELECT-AML-1, including combinations with venetoclax and azacitidine.

The company has emphasized that HR-MDS and AML are closely related diseases and that a substantial proportion of patients in these settings exhibit RARA overexpression, which provided the biological rationale for targeting RARα with tamibarotene.

Clinical development programs

Syros’ communications describe several key clinical programs:

• SELECT-MDS-1 Phase 3 trial in HR-MDS: a multinational, randomized, double-blind, placebo-controlled study evaluating tamibarotene plus azacitidine versus placebo plus azacitidine in newly diagnosed higher-risk MDS patients with RARA overexpression. The primary endpoint was complete response (CR) rate in the first 190 patients. Syros later reported that SELECT-MDS-1 did not meet its primary endpoint and that the difference in CR rate between the treatment and control arms was not statistically significant.
• SELECT-AML-1 Phase 2 trial in AML: a randomized trial evaluating a triplet regimen of tamibarotene, venetoclax and azacitidine compared with the doublet of venetoclax and azacitidine in newly diagnosed, unfit AML patients with RARA overexpression. Following a prespecified interim futility analysis, Syros announced that it would discontinue further enrollment in SELECT-AML-1 because the probability of demonstrating superiority at the final analysis was considered low, although no new safety signals were identified.

Earlier Syros-sponsored studies, as referenced in company communications, had suggested activity for tamibarotene in AML and HR-MDS with RARA overexpression, and these data supported the decision to advance tamibarotene into later-stage trials. However, the failure of the SELECT-MDS-1 Phase 3 trial to meet its primary endpoint had significant implications for the company’s development plans and financial position.

Business status and wind-down

In a subsequent announcement, Syros disclosed that the failure of the SELECT-MDS-1 trial to achieve its primary endpoint constituted an event of default under its secured loan facility with Oxford Finance LLC. The company stated that it had agreed to operate its business as a wind-down and to limit expenditures in line with a budget approved by its lender. Syros’ Board of Directors indicated that it was taking steps designed to preserve sufficient cash to fund an orderly wind down of operations and to maximize its cash position for the benefit of stakeholders.

Syros also announced that its Board had approved a voluntary delisting of its common stock from the Nasdaq Global Select Market and the deregistration of its common stock under the Securities Exchange Act of 1934. The company stated that it intended to file a Form 25 with the U.S. Securities and Exchange Commission to effect the delisting and deregistration, and to file a Form 15 to suspend its reporting obligations. Syros indicated that, after the effectiveness of the deregistration, it would no longer be required to file periodic reports under the Exchange Act.

Asset transactions

As part of its later-stage activities, Syros has been associated with tamibarotene-related clinical and non-clinical assets that were the subject of a transaction with Rege Nephro Co., Ltd. Rege Nephro reported that it acquired tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, including clinical and non-clinical data, human safety study data for potential New Drug Application use, contracts with a contract manufacturing organization, and tamibarotene active pharmaceutical ingredient and drug products. Syros had previously conducted a Phase 3 clinical trial of tamibarotene for indications including myelodysplastic syndrome and acute myeloid leukemia.

Therapeutic approach

Across its public disclosures, Syros has described tamibarotene as an oral, selective RARα agonist being developed for frontline patients with higher-risk MDS and, in some communications, AML with RARA gene overexpression. The company’s approach has been characterized by targeting a biologically defined subset of patients whose disease is driven by RARA overexpression, with the goal of improving outcomes in combination with existing standard therapies.

Industry classification

Based on the information provided, Syros Pharmaceuticals operates in the pharmaceutical preparation manufacturing industry within the broader manufacturing sector, with a focus on biopharmaceutical research and development in hematologic malignancies.

Historical context for investors

For investors reviewing the SYRS symbol, it is important to recognize that Syros has publicly described its business as being in wind-down following key clinical and financial developments. The company has announced its intention to delist from Nasdaq and deregister its common stock, and has indicated that it will limit operations in accordance with a wind-down budget approved by its lender. Historical information about Syros therefore primarily reflects its past efforts to develop tamibarotene for HR-MDS and AML with RARA overexpression, rather than ongoing growth-oriented operations.